Literature DB >> 14644808

Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome.

Jerome F Strauss1.   

Abstract

Polycystic ovary syndrome (PCOS) is a common disorder of unknown etiology, but several lines of evidence suggest that there is an underlying genetic cause for PCOS. Studies of first-degree relatives of women diagnosed with PCOS reveal familial clustering of the disease, particularly hyperandrogenemia. A prospective study of first-degree female relatives of PCOS women found that 46% of ascertainable sisters of PCOS women were hyperandrogenemic. The serum bioavailable testosterone in the cohort of sisters showed a bimodal distribution. These observations suggest a dominantly inherited trait controlling androgen levels. Studies on cultures of human theca cells derived from follicles isolated from the ovaries of PCOS and normal women demonstrated that PCOS theca cells produce greater amounts of testosterone, 17alpha-hydroxyprogesterone, and progesterone than normal theca cells, despite the fact that cells were cultured under identical conditions for multiple population doublings. Examination of the metabolism of radiolabeled steroid hormone precursors and steady-state levels of mRNAs encoding steroidogenic enzymes revealed that there are multiple alterations in the steroidogenic machinery of PCOS theca cells, including elevated expression of the CYP11A, 3BHSD2, and CYP17 genes. The increased mRNA levels are the result, in least in part, of increased gene transcription. Interestingly, the STAR gene is not expressed at a higher level in PCOS theca cells. The stable up-regulation of steroidogenesis in PCOS thecal cells indicates either a genetic abnormality in these cells or a persistent metabolic imprint established in vivo. Linkage and association studies conducted by the National Cooperative Program in Infertility Research using affected sib-pair analysis and the transmission/disequilibrium test to explore candidate genes point a finger at a region on chromosome 19p13.3. The putative PCOS gene lying in this region has yet to be identified. However, existing data suggest that it is probably involved in signal transduction mechanisms leading to altered expression of a suite of genes that affect theca cell steroidogenic activity as well as the metabolic phenotype of other cell types, including muscle and fat.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644808     DOI: 10.1196/annals.1290.005

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  18 in total

1.  Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches.

Authors:  Uche Anadu Ndefo; Angie Eaton; Monica Robinson Green
Journal:  P T       Date:  2013-06

Review 2.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15

Review 3.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

4.  miRNA Profiling Reveals miRNA-130b-3p Mediates DENND1A Variant 2 Expression and Androgen Biosynthesis.

Authors:  Jan M McAllister; Angela X Han; Bhavi P Modi; Maria E Teves; Grace R Mavodza; Zachary L Anderson; Tsaiwei Shen; Lane K Christenson; Kellie J Archer; Jerome F Strauss
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

Review 5.  Diagnostic criteria for polycystic ovarian syndrome.

Authors:  F J Broekmans; B C J M Fauser
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

6.  Endocrine and Metabolic Profile of Different Phenotypes of Polycystic Ovarian Syndrome.

Authors:  Saxena Pikee; Singh Shivani; Bhattacharjee Jayshree
Journal:  J Obstet Gynaecol India       Date:  2016-05-04

7.  A subpathway-based method of drug reposition for polycystic ovary syndrome.

Authors:  Hai-Ying Liu; Jian-Qiao Liu; Zi-Xin Mai; Yan-Ting Zeng
Journal:  Reprod Sci       Date:  2014-07-11       Impact factor: 3.060

8.  Structures of human steroidogenic cytochrome P450 17A1 with substrates.

Authors:  Elyse M Petrunak; Natasha M DeVore; Patrick R Porubsky; Emily E Scott
Journal:  J Biol Chem       Date:  2014-10-09       Impact factor: 5.157

9.  Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype.

Authors:  Jan M McAllister; Bhavi Modi; Bruce A Miller; Jessica Biegler; Richard Bruggeman; Richard S Legro; Jerome F Strauss
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-31       Impact factor: 11.205

10.  Loss of PKBβ/Akt2 predisposes mice to ovarian cyst formation and increases the severity of polycystic ovary formation in vivo.

Authors:  David F Restuccia; Debby Hynx; Brian A Hemmings
Journal:  Dis Model Mech       Date:  2012-01-24       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.